ExpreS2ion Biotech Holding
1.16 SEK -0.17%HC Andersen Capital receives payment from ExpreS2ion Biotech Holding for a DigitalIR/Corporate Visibility agreement. See disclaimer.
ExpreS2ion is a Danish-based biotech company listed in Sweden. The company develops a portfolio of vaccines for diseases such as COVID-19, influenza, and breast cancer through the use of its non-viral cell-based expression system, ExpreS2, which is recognized for handling protein challenges. ExpreS2ion has developed Expres2, which is a technology platform for efficient and fast non-clinical development and production of complex proteins for new vaccines and diagnostics. The company’s current primary product is the corona vaccine candidate, ABNCoV2 in phase 2, co-developed with its partner, AdaptVac of which ExpreS2ion owns 34%. The vaccine candidate has been licensed to Bavarian Nordic has global commercialization rights and responsibility for further clinical development of the vaccine and is expected to initiate phase 3 testing for the product candidate in the first half of 2022.
Read moreAnalyst
![Henrik Ekman Henrik Ekman](https://www.inderes.se/cdn-cgi/image/format=auto,width=128,height=128,quality=90,fit=cover/https://content.inderes.se/assets/6e03ef5d-f5bb-4113-a20b-1a7d036027c4.png)
![Claus Thestrup Claus Thestrup](https://www.inderes.se/cdn-cgi/image/format=auto,width=128,height=128,quality=90,fit=cover/https://content.inderes.se/assets/637ef734-dcbf-426c-bf91-0ac4a79aa71e.png)
Latest videos
Financial calendar
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Saxo Bank A/S Client Assets | 9.2 % | 9.2 % |
BNY Mellon SA/NV for Jyske Ban | 5.6 % | 5.6 % |
Premium
This content is for our Premium customers only.
ExpreS2ion Biotechnologies: ExpreS2ion announces poster presentation on the use of glycoengineered Drosophila S2 cells for production of highly immunogenic antigens at the ESACT meeting
ExpreS2ion Biotechnologies: Publication of clinical Phase Ib trial data for the adjuvanted RH5.1 blood-stage malaria vaccine
Join Inderes community
Don't miss out - create an account and get all the possible benefits
FREE account
PREMIUM account
ExpreS2ion Biotechnologies: ExpreS2ion hosts informative webinar on 2024 Rights Issue and Highlights Key Updates on HER2+ Breast Cancer Vaccine
![ExpreS2ion Biotechnologies – Rights Issue 2024 (Recording)](https://www.inderes.se/cdn-cgi/image/format=auto,width=640,height=358,quality=90,fit=contain/https://content.inderes.se/assets/ca70e718-91f4-4b0d-a261-f54bf0bef66f.png)
ExpreS2ion Biotechnologies – Rights Issue 2024 (Recording)
![ExpreS2ion Biotechnologies – Rights Issue 2024](https://www.inderes.se/cdn-cgi/image/format=auto,width=640,height=358,quality=90,fit=cover/https://content.inderes.se/assets/ca70e718-91f4-4b0d-a261-f54bf0bef66f.png)
ExpreS2ion Biotechnologies – Rights Issue 2024
ExpreS2ion Biotechnologies: BioStock: Rights issue takes Expres2ion breast cancer vaccine to phase I
ExpreS2ion Biotechnologies: ExpreS2ion CEO to BioStock: "Compelling preclinical package gives us confidence"
ExpreS2ion Biotechnologies: The subscription period in ExpreS2ion's rights issue begins today
ExpreS2ion Biotechnologies: ExpreS2ion to present in upcoming investor and scientific events
![HCA Capital: Wrap up from 2024 Life Science seminar](https://www.inderes.se/cdn-cgi/image/format=auto,width=640,height=358,quality=90,fit=contain/https://content.inderes.se/assets/ab49c0b1-56d0-4e1c-b729-6c79c89b7be2.png)
HCA Capital: Wrap up from 2024 Life Science seminar
ExpreS2ion Biotechnologies: ExpreS2ion publishes prospectus in connection with its rights issue of units
ExpreS2ion Biotechnologies: Bulletin from the Annual General Meeting of ExpreS2ion Biotech Holding AB held on 5 June 2024
![Life Science seminar 2024](https://www.inderes.se/cdn-cgi/image/format=auto,width=640,height=358,quality=90,fit=cover/https://content.inderes.se/assets/ab49c0b1-56d0-4e1c-b729-6c79c89b7be2.png)
Life Science seminar 2024
![ExpreS2ion Biotechnologies - Presentation of Q1 Report 2024 (Recording)](https://www.inderes.se/cdn-cgi/image/format=auto,width=640,height=358,quality=90,fit=contain/https://content.inderes.se/assets/ca70e718-91f4-4b0d-a261-f54bf0bef66f.png)
ExpreS2ion Biotechnologies - Presentation of Q1 Report 2024 (Recording)
![ExpreS2ion Biotechnologies - Presentation of Q1 Report 2024](https://www.inderes.se/cdn-cgi/image/format=auto,width=640,height=358,quality=90,fit=cover/https://content.inderes.se/assets/4638bb56-4d86-41af-b93c-407a41f11a8c.png)